International Market Access

MediPath Innovation Roadmap™

Stage 7 builds upon the foundations established in Stages 1–6, strategy, development, validation, clinical evidence, and compliance to enable companies to navigate the complexities of international markets. By integrating market prioritisation, regulatory scalability, reimbursement strategy, and value demonstration, this stage ensures that innovative MedTech solutions move beyond market entry and achieve sustainable adoption, funding, and impact at scale.

This section of MediPath covers various aspects of International Market Access including:

• Market Segmentation & Prioritisation 
• International Regulatory Documentation & Process 
• Reimbursement & Funding Pathways 
• Health Economics & Value Demonstration  
• Market Entry Strategy  

Following regulatory approval, MedTech companies are often faced with a wide range of potential global markets, each with varying degrees of opportunity, complexity, and accessibility. The instinct to launch into the largest or most well-known markets such as the US, Singapore, China or India can be tempting; however, this approach often leads to prolonged timelines, increased costs, and delayed commercial return. Too often, companies approach international expansion opportunistically reacting to distributor interest, investor pressure, or perceived market size. This results in fragmented efforts, duplication of regulatory work, and misalignment with local healthcare systems. 

A structured approach to international market access avoids these pitfalls and focuses on five critical pillars: 

1. Market Segmentation & Prioritisation 

Market segmentation and prioritisation provide a structured methodology to identify where a product is most likely to succeed first. segmentation requires a structured, analytical approach that divides the global landscape into meaningful categories based on shared characteristics such as healthcare system structure, regulatory complexity, reimbursement maturity, and clinical adoption pathways. This enables companies to move beyond a one-size-fits-all strategy and instead recognise that each market operates within its own ecosystem of stakeholders, incentives, and barriers to entry. By understanding these nuances, companies can begin to identify where their product is not only needed, but where it can realistically be adopted and funded. 

Prioritisation builds on this segmentation by introducing a strategic view through which markets are ranked and sequenced. This is more than considering the financial aspects or market size alone, but looks much more deeply into speed to access, likelihood of adoption, and long-term scalability. For example, a market with a clear reimbursement pathway but smaller patient population may offer faster early traction than a larger, more complex system with uncertain funding routes. In this way, prioritisation becomes a tool to optimise resource.

Medilink has developed a proprietary qualitative methodology to support market segmentation and prioritisation, incorporating a range of critical criteria that influence international market access success. These include factors such as healthcare spend and governance structures, regulatory complexity, reimbursement maturity, Corruption Perceptions Index (CPI) scores, procurement pathway, ease of adoption and overall commercial opportunity. By systematically assessing these dimensions, alongside other relevant market-specific considerations, this framework enables companies to make informed, evidence-based decisions on which markets to prioritise, balancing accessibility, risk, and long-term commercial potential. 

2. International Regulatory Documentation & Process

The transition from Stage 6 (Regulatory & Quality Compliance) to Stage 7 (International Market Access) represents a critical evolution in how regulatory strategy is applied. In Stage 6, the focus is on achieving approval within a primary market such as UKCA, CE marking, or other prioritised market through the compilation of comprehensive technical documentation, robust clinical evidence, and a compliant quality management system. This enables the device to be legally placed on the market. Although regulatory requirements differ globally, the core principles such as technical documentation, clinical evidence, and quality systems remain consistent. 

However, international expansion introduces a new level of complexity. While regulatory frameworks differ across jurisdictions, the underlying principles such as conformity assessment, technical documentation review, and quality system oversight remain broadly consistent.  This creates an opportunity for companies to move beyond single-market compliance and instead adopt a global regulatory strategy, where documentation and processes are designed from the outset to support multiple submissions.  

Rather than treating each international submission as a separate, isolated exercise, companies must structure their technical documentation such as the Design History File (DHF), Clinical Evaluation Report (CER), and post-market surveillance plans in a way that can be adapted across different regulatory environments. This requires foresight, ensuring that evidence generated in earlier MediPath stages is robust, transferable, and aligned with the expectations of multiple regulators.

The global regulatory landscape is evolving rapidly, meaning that even for UK-based companies, international market access strategies must remain flexible and adaptive. For example, the recent publication of the Statutory Instrument (SI) for the UK Medical Devices Regulation 2026 (amended) shows that future change will significantly influence market entry pathways.

These changes are anticipated to enable access to the UK market for devices already approved in jurisdictions such as the United States, Canada, and Australia, highlighting the importance of aligning global strategy with emerging regulatory developments. These changes are anticipated to enable access to the UK market for devices already approved in jurisdictions such as the United States, Canada, and Australia, highlighting the importance of aligning global strategy with emerging regulatory developments. 

As medical technologies increasingly integrate software components whether as Software as a Medical Device (SaMD) or more advanced AI-enabled functionalities within devices (AIaMD), it is essential to align not only with core medical device regulations but also with digital health governance frameworks such as DTAC, DCB0160, and DCB0129 in the UK, alongside equivalent requirements in other international markets. Ensuring compliance with these frameworks supports robust clinical risk management, data governance, cybersecurity, and system interoperability, which are particularly critical as regulators globally strengthen oversight of software- and AI-driven capabilities embedded within medical technologies. 

Companies must also navigate differences between regulatory systems, including device classification, evidence requirements, and review processes. For example, while a CE-marked device may rely on conformity assessment through a Notified Body, entry into the US market may require a 510(k) submission, De Novo route, or Premarket Approval (PMA), each with its own evidentiary standards and timelines.  Similarly, markets such as China (NMPA), Japan (PMDA), Australia (TGA), or Saudi Arabia (SFDA) introduce additional regulatory nuances that must be addressed. Regulatory reliance mechanisms allow certain markets to partially recognise approvals granted by trusted authorities, reducing duplication and accelerating access. 

Another critical element of this pillar is the management of post-market obligations. Regulatory compliance does not end at approval; it continues throughout the product lifecycle. Activities such as post-market surveillance (PMS), which can also include post-market clinical follow-up (PMCF), and the need to produce periodic safety reporting must be maintained and tailored to each market.  These ongoing requirements not only ensure continued compliance but also generate real-world data that can support market access, reimbursement, and expansion. International Regulatory Documentation & Process is about transforming regulatory compliance from a static, approval-focused activity into a dynamic, globally integrated capability. It ensures that the significant investment made in regulatory readiness during earlier stages of MediPath can be leveraged efficiently across multiple markets, reducing duplication, controlling costs, and accelerating time to international adoption. 

There’s general convergence of regulatory requirements with the potential exception of digital health, where many regulatory requirements are subject to consultation and evolving at a rapid rate. 

3. Reimbursement & Funding Pathways

Reimbursement and funding pathways represent one of the most decisive factors in determining whether an approved medical technology will actually achieve adoption within a healthcare system. Healthcare systems across global markets operate under different financial models, ranging from publicly funded systems such as the NHS, to insurance-based systems such as the United States, as well as hybrid structures seen across Europe, the Middle East, and Asia. Each of these models introduces distinct reimbursement mechanisms, decision-making processes, and evidence requirements. As such, a product that achieves rapid uptake in one market may face significant barriers in another if funding pathways are unclear or misaligned. 

At its core, reimbursement strategy is about ensuring that a product is not only clinically valuable, but also financially viable within the context of a specific healthcare system. This requires a deep understanding of how value is assessed by payers whether national bodies, private insurers, or individual hospital systems and how decisions are made regarding coverage and payment. In many cases, reimbursement decisions rely on evidence that extends beyond regulatory requirements, including comparative effectiveness, economic impact, and long-term outcomes. 

A key challenge for MedTech companies is that reimbursement pathways are often more fragmented and less predictable than regulatory processes. Regulatory approval follows defined standards and submission pathways, whereas reimbursement decisions may involve multiple stakeholders, including clinicians, procurement bodies, payers, and health technology assessment (HTA) organisations. This creates a more complex and iterative process, where demonstrating clinical efficacy is necessary but not sufficient to secure adoption.  

Furthermore, reimbursement is closely tied to coding, coverage, and payment mechanisms, particularly in markets such as the US. Without appropriate coding systems (e.g., CPT (Current Procedural Terminology), HCPCS (Healthcare Common Procedure Coding System), and ICD (International Classification of Diseases) structures) in place, even an approved product may not be recognised within reimbursement frameworks, limiting its use. Similarly, in publicly funded systems, procurement processes and budget constraints may influence whether a technology is adopted at scale, regardless of its clinical benefit. When a specific code does not exist, companies must adopt a strategic and often phased approach to ensure their technology can still be billed, recognised, and reimbursed within the healthcare system. 

Ultimately, Reimbursement & Funding Pathways serve as the bridge between approval and adoption, ensuring that innovative technologies can move beyond regulatory clearance to become embedded within healthcare systems. Companies that fail to align with reimbursement requirements risk stalling at the point of market entry, while those that proactively address funding pathways are better positioned to achieve sustainable, scalable adoption across global markets. 

Markets with clear reimbursement routes often present faster adoption opportunities than those with larger but less defined funding systems. 

4. Health Economics & Value Demonstration

Health economics and value demonstration represent the final and arguably most critical layer of international market access, where innovation is no longer judged purely on clinical performance, but on its ability to deliver tangible value within a healthcare system. By this stage in the MediPath Innovation Roadmap™, companies have already generated clinical evidence, achieved regulatory approval, and begun navigating reimbursement pathways. However, in increasingly constrained and value-driven healthcare environments, these achievements alone are not sufficient to secure widespread adoption. 

The value proposition, initially defined in Stage 3 of the MediPath Innovation Roadmap™, must be refined and tailored to each target market in Stage 7 to reflect local clinical, economic, and system-level priorities. Any gaps identified between the proposed value and market expectations should be addressed through clinical investigation or post-market clinical follow-up activities, with a strong focus on generating real-world evidence, representing a key shift from early-stage conceptual value definition to validated, market-relevant impact. 

Currently, healthcare systems are under significant pressure to balance quality of care with cost efficiency. As a result, decision-making is shifting away from purely efficacy-based assessments towards value-based healthcare models, where technologies must demonstrate not only that they work, but that they deliver meaningful improvements relative to their cost. This shift fundamentally changes the expectations placed on MedTech innovators, requiring them to articulate clearly how their product impacts both patient outcomes and system-level performance. 

Health economics provides the framework through which this value is quantified and communicated. It involves evaluating the relationship between costs and outcomes, often through methodologies such as cost-effectiveness analysis, budget impact modelling, and cost-utility assessments. These approaches enable companies to demonstrate how their technology compares to existing standards of care not just in terms of clinical benefit, but in terms of economic efficiency and resource utilisation. Importantly, this analysis must reflect the realities of individual healthcare systems, where cost structures, funding constraints, and treatment pathways can vary significantly between markets. 

Value demonstration extends beyond formal economic modelling to include a broader consideration of how a product contributes to healthcare system priorities. This may include reducing hospital admissions, shortening length of stay, improving workflow efficiency, or enabling earlier intervention and prevention. In this context, value is multi-dimensional involving clinical outcomes, operational efficiency, and long-term system sustainability. The ability to communicate this effectively to different stakeholders, including clinicians, payers, procurement bodies, and policymakers, is essential for successful adoption. 

A critical aspect of this pillar is that it must be embedded early in the innovation lifecycle, rather than developed retrospectively after approval. As highlighted in earlier MediPath stages, particularly Stage 5 (clinical development), evidence generation should be designed not only to meet regulatory requirements, but also to support health economic evaluation. This ensures that clinical studies capture relevant endpoints such as survival rates, quality-of-life measures, resource utilisation, frequency of re-admissions, number of bed days, and long-term outcomes that can feed directly into economic models and reimbursement submissions. 

Furthermore, health economics plays a pivotal role in supporting both reimbursement and market expansion. Strong value evidence can accelerate payer decisions, justify pricing strategies, and differentiate a product in competitive markets. It also strengthens the case for adoption across different geographies, as economic data and real-world evidence generated in initial markets can be used to inform submissions and decision-making in subsequent regions. 

The health economic case for adoption can also be communicated through clear, visual diagrammatic formats that incorporate comparative data from leading and competing solutions, enabling decision-makers to quickly and effectively understand the value and benefits the technology delivers. 

5. Market Entry Strategy

A market entry strategy helps the innovator to mover from the technical and regulatory phase to actually introducing the product into market specific healthcare system. This part of market access is more on the operation execution, after identifying the priority market and developing a broader global market access strategy, the focus shifts to how a company will practically enter, position, and establish its product within a chosen market. As discussed, each healthcare market operates differently, with its own structure of providers, payers, procurement processes, and clinical pathways. As a result, market entry cannot be treated as a standardised rollout. Instead, it requires a tailored approach that reflects how decisions are actually made within that system, including who influences adoption, how technologies are funded, and what evidence is required to support uptake. 

Market entry strategy involves selecting an appropriate route-to-market model, whether through local distributors, strategic partnerships, or direct commercial presence. These decisions are not completely commercial as they must also align with regulatory requirements, reimbursement pathways, and the level of local expertise needed to navigate complex healthcare environments. In more fragmented systems, such as the US, partnering with organisations that understand local procurement, coding, and clinical adoption processes can be essential to gaining early traction. Equally in other markets, the concept of early adoption and pilot introduction may be beneficial. In many healthcare systems, new technologies are not immediately adopted at scale but are first evaluated through pilot programmes, early adopter sites, or innovation pathways. These initial deployments provide an opportunity to generate real-world evidence, validate the product within clinical workflows, and build credibility among key stakeholders. Rather than viewing this as a limitation, innovators use these early stages strategically to refine value proposition, strengthen evidence base, and create a foundation for broader expansion. 

Therefore, well-defined market entry strategy also requires a clear understanding of cost, investment, and return on value. Entering a new market involves significant expenditure across regulatory submissions, commercial infrastructure, stakeholder engagement, and evidence generation. Companies must therefore assess whether the potential revenue, strategic positioning, or expansion opportunity justifies the investment. Another key consideration is alignment with local clinical pathways and workflows. Even highly innovative technologies can struggle to gain adoption if they disrupt established practices or require significant changes to how care is delivered. A successful market entry strategy ensures that the product integrates seamlessly into existing systems. This requires early engagement with clinicians, providers, and healthcare organisations to understand practical implementation challenges and opportunities. 

Initial market entry strategies should provide detail on how the product will scale over time, including expanding into additional institutions, securing broader reimbursement coverage, and strengthening stakeholder relationships. Early decisions around partnerships, pricing, and positioning have long-term implications for how easily a company can grow within that market. 

Medilink’s specialist team can support companies throughout the entire international market access journey providing strategic guidance. Whether organisations are at the early planning phase, defining target markets, assessing regulatory and reimbursement pathways—or require practical, advise navigating entry, adoption, and scaling, Medilink offers a fully integrated approach. By combining regulatory insight, market analysis, reimbursement strategy, and commercial expertise, the team helps ensure that MedTech innovations move efficiently from concept to successful adoption within global healthcare systems. 

Stage 7 of the MediPath Innovation Roadmap™ represents the point at which technology is translated into real-world impact, integrating strategic market selection, scalable regulatory documentation, reimbursement alignment, value demonstration, and effective market entry into a cohesive pathway for success. By systematically addressing market segmentation and prioritisation, navigating international regulatory processes, securing reimbursement and funding routes, and demonstrating clear health economic value, companies are positioned not only to enter markets but to achieve meaningful adoption. Combined with a well-defined market entry strategy, Stage 7 ensures that MedTech innovations move beyond approval to become embedded within healthcare systems, delivering sustainable clinical, economic, and commercial outcomes at scale. 

Tailor your roadmap to your device – free consultation

The Specialist Consultancy Team offer innovation, commercialisation, regulatory and international market access services, covering the full MediPath journey, with end-to-end support, helping to de-risk and fast-track innovation and increase the probability of commercial success.

If you would like to discuss any of these stages or to understand how the roadmap can de-risk your innovation and accelerate the speed to market, we are offering a free 30-minute consultation. Contact us on [email protected]

Patrick Trotter PhD MBA (TechMgmt), Stefanie Read MSc, Rashmi Raju PhD